Treatment duration and long-term outcomes with daratumumab in transplant-ineligible newly diagnosed multiple myeloma from the phase 3 MAIA study

被引：0

作者：

Moreau, Philippe ^{[1
]}

Facon, Thierry ^{[2
]}

Usmani, Saad ^{[3
]}

Kumar, Shaji ^{[4
]}

Plesner, Torben ^{[5
,6
]}

Goldschmidt, Hartmut ^{[7
,8
]}

Orlowski, Robert ^{[9
]}

Perrot, Aurore ^{[10
]}

Chari, Ajai ^{[11
]}

Cook, Gordon ^{[12
]}

Pei, Huiling ^{[13
]}

Van Rampelbergh, Rian ^{[14
]}

Bartlett, J. Blake ^{[15
]}

Uhlar, Clarissa ^{[16
]}

Carson, Robin ^{[16
]}

Bahlis, Nizar ^{[17
]}

机构：

[1] Univ Hosp Hotel Dieu, Dept Hematol, Nantes, France

[2] Univ Lille, CHU Lille, Serv Malad Sang, Lille, France

[3] Mem Sloan Kettering Canc Ctr, New York, NY USA

[4] Mayo Clin Rochester, Dept Hematol, Rochester, MN USA

[5] Vejle Hosp, Vejle, Denmark

[6] Univ Southern Denmark, Vejle, Denmark

[7] Univ Hosp Heidelberg, Internal Med 5, Heidelberg, Germany

[8] Natl Ctr Tumor Dis NCT, Heidelberg, Germany

[9] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma Myeloma, Houston, TX USA

[10] Inst Univ Canc Toulouse Oncopole, Toulouse, France

[11] Icahn Sch Med Mt Sinai, New York, NY USA

[12] Leeds Inst Clin Trials Res, Leeds Canc Res UK CTU, Leeds, W Yorkshire, England

[13] Janssen Res & Dev LLC, Titusville, NJ USA

[14] Janssen Res & Dev, Beerse, Belgium

[15] Janssen Res & Dev LLC, Raritan, NJ USA

[16] Janssen Res & Dev LLC, Spring House, PA USA

[17] Univ Calgary, Calgary, AB, Canada

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2022年 / 22卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

OAB-039

引用

页码：S23 / S24

页数：2

共 50 条

[1] Daratumumab/lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA long-term outcomes
Facon, Thierry
Moreau, Philippe
Weisel, Katja
Goldschmidt, Hartmut
Usmani, Saad Z.
Chari, Ajai
Plesner, Torben
Orlowski, Robert Z.
Bahlis, Nizar
Basu, Supratik
Hulin, Cyrille
Quach, Hang
O'Dwyer, Michael
Perrot, Aurore
Jacquet, Caroline
Venner, Christopher P.
Raje, Noopur
Tiab, Mourad
Macro, Margaret
Frenzel, Laurent
Leleu, Xavier
Cook, Gordon
Wang, George
Pei, Huiling
Krevvata, Maria
Carson, Robin
Borgsten, Fredrik
Kumar, Shaji K.
LEUKEMIA, 2025, : 942 - 950
[2] Incidence, Timing, and Management of Infections in Patients Receiving Daratumumab for the Treatment of Newly Diagnosed Transplant-Ineligible Multiple Myeloma in the MAIA Study
Bahlis, Nizar J.
Facon, Thierry
Usmani, Saad
Moreau, Philippe
Raje, Noopur
Zweegman, Sonja
Chari, Ajai
Perrot, Aurore
Manier, Salomon
Orlowski, Robert
Goldschmidt, Hartmut
Basu, Supratik
Hulin, Cyrille
Weisel, Katja
Mohty, Mohamad
Plesner, Torben
Cook, Gordon
Leleu, Xavier
Quach, Hang
Venner, Christopher P.
Ngo, Mai
Bolyard, Kasey
Carson, Robin
Borgsten, Fredrik
Kumar, Shaji
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S221 - S221
[3] Overall survival and progression-free survival by treatment duration with Daratumumab plus Lenalidomide/Dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: phase 3 MAIA study
Moreau, Philippe
Facon, Thierry
Kumar, Shaji
Plesner, Torben
Orlowski, Robert Z.
Bahlis, Nizar
Basu, Supratik
Nahi, Hareth
Hulin, Cyrille
Quach, Hang
Goldschmidt, Hartmut
O'Dwyer, Michael
Perrot, Aurore
Venner, Christopher
Weisel, Katja
Mace, Joseph R.
Raje, Noopur
Tiab, Mourad
Macro, Margaret
Frenzel, Laurent
Leleu, Xavier
Pei, Huiling
Tromp, Brenda
Delioukina, Maria
Usmani, Saad Z.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S1 - S1
[4] Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA
Facon, Thierry
Cook, Gordon
Usmani, Saad Z.
Hulin, Cyrille
Kumar, Shaji
Plesner, Torben
Touzeau, Cyrille
Bahlis, Nizar J.
Basu, Supratik
Nahi, Hareth
Goldschmidt, Hartmut
Quach, Hang
Mohty, Mohamad
Venner, Christopher P.
Weisel, Katja
Raje, Noopur
Hebraud, Benjamin
Belhadj-Merzoug, Karim
Benboubker, Lotfi
Decaux, Olivier
Manier, Salomon
Caillot, Denis
Ukropec, Jon
Pei, Huiling
Van Rampelbergh, Rian
Uhlar, Clarissa M.
Kobos, Rachel
Zweegman, Sonja
LEUKEMIA, 2022, 36 (04) : 1066 - 1077
[5] Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA
Thierry Facon
Gordon Cook
Saad Z. Usmani
Cyrille Hulin
Shaji Kumar
Torben Plesner
Cyrille Touzeau
Nizar J. Bahlis
Supratik Basu
Hareth Nahi
Hartmut Goldschmidt
Hang Quach
Mohamad Mohty
Christopher P. Venner
Katja Weisel
Noopur Raje
Benjamin Hebraud
Karim Belhadj-Merzoug
Lotfi Benboubker
Olivier Decaux
Salomon Manier
Denis Caillot
Jon Ukropec
Huiling Pei
Rian Van Rampelbergh
Clarissa M. Uhlar
Rachel Kobos
Sonja Zweegman
Leukemia, 2022, 36 : 1066 - 1077
[6] Daratumumab: A Review in Combination Therapy for Transplant-Ineligible Newly Diagnosed Multiple Myeloma
Yahiya Y. Syed
Drugs, 2019, 79 : 447 - 454
[7] Daratumumab: A Review in Combination Therapy for Transplant-Ineligible Newly Diagnosed Multiple Myeloma
Syed, Yahiya Y.
DRUGS, 2019, 79 (04) : 447 - 454
[8] Daratumumab Plus Lenalidomide and Dexamethasone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Maia Age Subgroup Analysis
Facon, Thierry
Kumar, Shaji K.
Weisel, Katja
Usmani, Saad
Moreau, Philippe
Plesner, Torben
Orlowski, Robert Z.
Bahlis, Nizar Jacques
Basu, Supratik
Nahi, Hareth
Hulin, Cyrille
Quach, Hang
O'Dwyer, Michael
Perrot, Aurore
Venner, Christopher P.
Raje, Noopur
Tiab, Mourad
Macro, Margaret
Frenzel, Laurent
Leleu, Xavier
Pei, Huiling
Carson, Robin
Borgsten, Fredrik
Goldschmidt, Hartmut
BLOOD, 2022, 140 : 10133 - 10136
[9] Dose intensity and treatment duration of bortezomib in transplant-ineligible newly diagnosed multiple myeloma
Ibarra, Gladys
Pena, Marta
Abril, Laura
Senin, Alicia
Maluquer, Clara
Clapes, Victoria
Baca, Cristina
Bustamante, Gabriela
Sureda, Anna
Oriol, Albert
EUROPEAN JOURNAL OF HAEMATOLOGY, 2021, 107 (02) : 246 - 254
[10] Quadruplets in newly diagnosed transplant-ineligible multiple myeloma
Chakraborty, Rajshekhar
Mian, Hira
AMERICAN JOURNAL OF HEMATOLOGY, 2024, 99 (11) : 2249 - 2252

← 1 2 3 4 5 →